Shattuck Labs Business Summary

Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, research collaborations, and milestone payments, as it has yet to commercialize its proprietary pipeline. The company operates through a single business segment focused on the development of bi-functional fusion proteins designed to treat cancer and autoimmune diseases. Its core value proposition is built upon two distinct platforms: the Agonist Redirected Checkpoint (ARC) platform, which combines checkpoint blockade with tumor necrosis factor (TNF) receptor agonism, and the GADLEN platform, which targets gamma delta T-cell engagers. Shattuck’s lead clinical candidates include SL-172154, targeting CD47 and CD40 for hematologic malignancies, and SL-325, a first-in-class DR3 antagonist for inflammatory bowel disease (IBD). In the competitive landscape, Shattuck contends with specialized biotech firms such as Iovance Biotherapeutics, Sana Biotechnology, and Ventyx Biosciences, positioning itself as a pioneer in the "dual-action" protein engineering space that seeks to consolidate multiple immune functions into a single therapeutic molecule. The company was co-founded by CEO Dr. Taylor H. Schreiber and Josiah Hornblower, with Dr. Schreiber previously serving as the Chief Scientific Officer of Heat Biologics and holding an M.D./Ph.D. from the University of Miami. The executive leadership team includes Chief Technical Officer Dr. Abhinav A. Shukla, who brings extensive manufacturing expertise from KBI Biopharma and Bristol-Myers Squibb, and Chief Financial Officer Andrew R. Neill, formerly of Genzyme and Sanofi. Clinical operations are led by Chief Medical Officer Dr. Arunthathy "Lini" Pandite, a veteran of GlaxoSmithKline’s oncology division. Shattuck is backed by prominent institutional investors, most notably OrbiMed Advisors, which led a significant $103 million private placement in late 2025. The Board of Directors features industry experts such as Dr. Daniel Baker and OrbiMed’s Dr. Mona Ashiya, reflecting a high-pedigree governance structure focused on navigating the transition from platform discovery to late-stage clinical validation.